[{"orgOrder":0,"company":"Key Oncologics","sponsor":"PharmaMar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Key Oncologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Key Oncologics \/ Key Oncologics","highestDevelopmentStatusID":"12","companyTruncated":"Key Oncologics \/ Key Oncologics"}]

Find Clinical Drug Pipeline Developments & Deals by Key Oncologics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : PharmaMar will retain exclusive production rights for Yondelis®(trabectedin), which will be sold to Key Oncologics for its clinical and commercial use in South Africa, Namibia and Botswana.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 19, 2020

                          Lead Product(s) : Trabectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : PharmaMar

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank